BridgeMD
A study to evaluate the efficacy and safety of JCAR017 in adult subjects with a type of cancer that affects B-cells, a type of white blood cell.
EU CTIS ID: 2024-510966-18-00
What this study is testing
The primary objective of the study is to evaluate the efficacy of JCAR017 in subjects with relapsed/refractory (r/r) follicular lymphoma (FL) and marginal zone lymphoma (MZL).
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Subject has FL (Grade 1, 2, or 3a) or MZL histologically confirmed within 6 months of screening, as assessed by local pathology.
- Subject has adequate vascular access for leukapheresis procedure.
- Subjects must agree to not donate blood, organs, sperm or semen, and egg cells for usage in other individuals for at least 1 year following lymphodepleting chemotherapy.
- Females of childbearing potential (FCBP) subjects must: a. Have 2 negative pregnancy tests as verified by the Investigator (one negative serum beta-human chorionic gonadotropin [ß-hCG] pregnancy test result at screening, and within 7 days prior to the first dose of lymphodepleting chemotherapy). b. Either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with, effective contraception without interruption. c. Agree to abstain from breastfeeding during study participation and for at least 12 months following lymphodepleting chemotherapy.
- Male subjects must: a. Practice true abstinence (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential for 12 months after lymphodepleting chemotherapy even if he has undergone a successful vasectomy.
- Refer to protocol section 4.2 for list of inclusion criteria.
You likely can't join if
- Evidence or history of composite DLBCL and FL, or of transformed FL. Subjects with World Health Organization (WHO) sub-classification of duodenal-type FL
- Active hepatitis B or active hepatitis C.
- Uncontrolled systemic fungal, bacterial, viral or other infection (including tuberculosis) despite appropriate antibiotics or other treatment.
- Active autoimmune disease requiring immunosuppressive therapy.
- Presence of acute or chronic graft-versus-host disease (GVHD).
- History of specific cardiovascular conditions within the past 6 months prior to signing the ICF (see protocol section 4.3).
See the full eligibility criteria
Who can join
- Subject has FL (Grade 1, 2, or 3a) or MZL histologically confirmed within 6 months of screening, as assessed by local pathology.
- Subject has adequate vascular access for leukapheresis procedure.
- Subjects must agree to not donate blood, organs, sperm or semen, and egg cells for usage in other individuals for at least 1 year following lymphodepleting chemotherapy.
- Females of childbearing potential (FCBP) subjects must: a. Have 2 negative pregnancy tests as verified by the Investigator (one negative serum beta-human chorionic gonadotropin [ß-hCG] pregnancy test result at screening, and within 7 days prior to the first dose of lymphodepleting chemotherapy). b. Either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with, effective contraception without interruption. c. Agree to abstain from breastfeeding during study participation and for at least 12 months following lymphodepleting chemotherapy.
- Male subjects must: a. Practice true abstinence (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential for 12 months after lymphodepleting chemotherapy even if he has undergone a successful vasectomy.
- Refer to protocol section 4.2 for list of inclusion criteria.
- Subject must have relapsed or refractory disease, as assessed by the investigator.
- Subject must have measurable disease as follows: a. For FL subjects (Cohorts 1, 2, 3 and 3 Extension), PET-positive disease with at least one PET-positive lesion and at least one measurable nodal or extranodal lesion greater than 1.5 cm in the long axis (refer to protocol, Appendix G) b. MZL subjects (Cohort 4) with PET non-avid disease should have at least one measurable nodal lesion greater than 2.0 cm in the long axis (PET-positive disease is not required for MZL) - refer to protocol, Appendix G.
- Subject must have received the following, depending on cohort assignment: a. Cohort 1 (4L+ r/r FL): received at least 3 prior lines of systemic therapy. At least one of these lines must be a combination which included an anti-CD20 antibody (eg, rituximab, obinutuzumab) and an alkylating agent. Prior HSCT is permitted as a prior line of therapy. A group of 4L+ double-refractory subjects will be enrolled in this cohort (refer to protocol section 4.2). b. Cohort 2 (3L r/r FL): received 2 prior lines of systemic therapy. At least one of these lines must be a combination which included an antiCD20 antibody (eg, rituximab, obinutuzumab) and an alkylating agent. Prior HSCT is permitted as a prior line of therapy. c. Cohort 3 (2L r/r FL): received 1 prior line of combination systemic therapy, which included an anti-CD20 antibody (eg, rituximab, obinutuzumab) and an alkylating agent. A group of POD24 subjects, defined as having progressive disease within 24 months of diagnosis and have received treatment within 6 months of the original FL diagnosis, will be enrolled to this cohort. The 2L subjects that do not meet this POD24 definition must instead meet one of the modified GELF criteria (NCCN, 2019) as outlined in protocol section 4.2, number 5. d.Cohort 3 Extension (2L r/r FL): received no more than 1 prior line of combination systemic therapy, which included an anti-CD20 antibody (eg, rituximab, obinutuzumab) and an alkylating agent, and i. has relapsed or refractory disease that has progressed within 24 months of initiation of first-line chemoimmunotherapy (POD24) OR ii. must meet at least one of the modified GELF criteria (NCCN, 2019), as outlined in Inclusion Criterion 5.e.Cohort 4 (3L+ r/r MZL): received at least 2 prior systemic therapies, including at least one line of combination systemic therapy, therapy with an anti-CD20 antibody (eg, rituximab, obinutuzumab) and an alkylating agent, or relapsed after HSCT. Splenectomy for Splenic MZL (SMZL) is considered as a line of therapy. Antibiotics for extranodal MZL (ENMZL) are not considered as a prior line of therapy.
- Cohort 3 (2L r/r FL) and Cohort 3 Extension (2L r/r FL) subjects must meet at least one criterion of the modified GELF criteria listed below (a-d) (NCCN, 2019) if they do not meet criteria of POD24 (as defined for Cohort 3 and Cohort 3 Extension respectively) a. Symptoms attributable to FL (not limited to B symptoms) b. Threatened end-organ function; OR cytopenia secondary to lymphoma; OR bulky disease (single mass > 7 cm or 3 or more masses > 3 cm) c. Splenomegaly d. Steady progression over at least 6 months
- Subject is ≥ 18 years of age the time of signing the informed consent form (ICF).
- Subjects who have received previous CD19-targeted therapy must have CD19-positive lymphoma confirmed on a biopsy since completing the prior CD19-targeted therapy
- Subject has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Subject has adequate organ function.
What rules you out
- Evidence or history of composite DLBCL and FL, or of transformed FL. Subjects with World Health Organization (WHO) sub-classification of duodenal-type FL
- Active hepatitis B or active hepatitis C.
- Uncontrolled systemic fungal, bacterial, viral or other infection (including tuberculosis) despite appropriate antibiotics or other treatment.
- Active autoimmune disease requiring immunosuppressive therapy.
- Presence of acute or chronic graft-versus-host disease (GVHD).
- History of specific cardiovascular conditions within the past 6 months prior to signing the ICF (see protocol section 4.3).
- History or presence of clinically relevant central nervous system (CNS) pathology not related to disease under study. (see protocol section 4.3)
- Subject is a pregnant or nursing (lactating) woman.
- Subject has an intolerance to dimethyl sulfoxide (DMSO) and/or dextran
- Progressive vascular tumor invasion, thrombosis, or embolism
- Venous thrombosis or embolism not managed on a stable regimen of anticoagulation
- Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study based on investigator's judgement.
- Subject has received or undergone the following (See section 4.3 for additional details).a. Therapeutic doses of corticosteroids (defined as >20 mg/day prednisone or equivalent) within 7 days prior to unstimulated leukapheresis. b. Cytotoxic chemotherapeutic agents that are not considered lymphotoxic and intrathecal chemotherapy must be stopped > 7 days prior to unstimulated leukapheresis c. Lymphotoxic chemotherapeutic agents (eg, cyclophosphamide > 300 mg/m2, ifosfamide, bendamustine) 2 weeks prior to unstimulated leukapheresis. d. Experimental agents within 4 weeks prior to signing the ICF unless no response or PD is documented on the experimental therapy e. Ibrutinib, lenalidomide and PI3Ki within 3 half-lives prior to unstimulated leukapheresis f. Immunosuppressive therapies within 4 weeks prior to leukapheresis and JCAR017 infusion g. Donor lymphocyte infusion (DLI) within 6 weeks prior to JCAR017 infusion h. Radiation within 6 weeks of leukapheresis. i. Systemic immunostimulatory agents within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to JCAR017 infusion. j. Allo-HSCT within 90 days of leukapheresis.
- Refer to protocol section 4.3 for list of inclusion criteria
- Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study based on investigator's judgement.
- Any condition that confounds the ability to interpret data from the study based on investigator's judgement.
- Central nervous system (CNS)-only involvement by malignancy (note: subjects with secondary CNS involvement are allowed on study).
- History of another primary malignancy that has not been in remission for at least 2 years For specific exceptions, see protocol section 4.3
- Previous treatment with alemtuzumab within 6 months of leukapheresis, or treatment with fludarabine or cladribine within 3 months of leukapheresis.
- Prior CAR T-cell or other genetically-modified cell therapy.
- History of or active human immunodeficiency virus (HIV).
The study team makes the final eligibility decision.
Where it's taking place
- Canada
- Japan
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Canada; Japan; United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.